Pub Date : 2019-12-01DOI: 10.4167/jbv.2019.49.4.203
H. Choi, Jae-Hyoung Song, Kyungah Yoon
Echovirus 30 is one of the major causes of meningitis in children and adults. The purpose of our current study was to investigate whether selected antiviral drugs could provide antiviral activity against echovirus 30. Using RD cells, we assessed the cytopathic effect of echovirus 30, including viral RNA levels as indicators of viral replication. The effects of gemcitabine were compared to rupintrivir, a well-known antiviral drug. To understand the activity gemcitabine exerts on the viral life cycle, time course and time-of-addition assays were implemented. The most effective compounds against echovirus 30 were gemcitabine and rupintrivir, as demonstrated by their concentration-dependent activity. Gemcitabine affects the early stages of echovirus 30 infection by disrupting viral replication. However, gemcitabine failed to directly inactivate echovirus 30 particles or impede viral uptake into the RD cells. Gemcitabine can be considered as a lead candidate in the development of echovirus 30 antiviral drugs, specifically in the early stages of echovirus 30 replication. Based on the results produced from the E30 in vitro assay, we conducted time course experiments to analyze the mechanism of action of gemcitabine. Viral RNA from E30 was detected using RT-PCR at various times points (4, 6, 8, 10, and 12 h post-infection) and after gemcitabine (10 M) and rupintrivir (2 M) treatment of E30-infected cells. We could find E30 viral RNA as early as 8 h post-infection. Interestingly, gemcitabine was seen to block the proliferation of E30 in resemblance to rupintrivir (inhibitor of picornavirus 3C protease, Fig. 2). Based on the results of the time course experiments, we hypothesized that the antiviral effect of gemcitabine occurs relatively early in the infection process. To observe which step is influenced by gemcitabine, we performed a time-of-addition experiment. Gemcitabine (10 M) and rupintrivir (2 M) were added to the culture medium at -1, 0, 1, 2, 4, 6, 8, 10 and 12 h after virus infection. E30 RNA replication was analyzed infection. Therefore, we concluded that the antiviral effect of gemcitabine occurs relatively early during viral infection. To realize the potential of gemcitabine as an antiviral candidate, its mechanism of activity must be understood. It is important to differentiate between viral inactivation (virucidal activity) from antiviral activity. Direct viral inactivation is an early event where the virus is inactivated before it infects the cells while antiviral activity involves killing the virus or the suppression of viral replication. It would be ideal for viral infection treatments to possess both virucidal and antiviral activities. In our study, gemcitabine did not directly interact with E30 particles as pre-exposure of the virus to gemcitabine did not alter the infectivity of E30 particles. Furthermore, addition of UTP and CTP significantly reduced the antiviral activity of gemcitabine by increasing the levels of pyrimidine
{"title":"Antiviral Activity of Gemcitabine Against Echovirus 30 Infectionin Vitro","authors":"H. Choi, Jae-Hyoung Song, Kyungah Yoon","doi":"10.4167/jbv.2019.49.4.203","DOIUrl":"https://doi.org/10.4167/jbv.2019.49.4.203","url":null,"abstract":"Echovirus 30 is one of the major causes of meningitis in children and adults. The purpose of our current study was to investigate whether selected antiviral drugs could provide antiviral activity against echovirus 30. Using RD cells, we assessed the cytopathic effect of echovirus 30, including viral RNA levels as indicators of viral replication. The effects of gemcitabine were compared to rupintrivir, a well-known antiviral drug. To understand the activity gemcitabine exerts on the viral life cycle, time course and time-of-addition assays were implemented. The most effective compounds against echovirus 30 were gemcitabine and rupintrivir, as demonstrated by their concentration-dependent activity. Gemcitabine affects the early stages of echovirus 30 infection by disrupting viral replication. However, gemcitabine failed to directly inactivate echovirus 30 particles or impede viral uptake into the RD cells. Gemcitabine can be considered as a lead candidate in the development of echovirus 30 antiviral drugs, specifically in the early stages of echovirus 30 replication. Based on the results produced from the E30 in vitro assay, we conducted time course experiments to analyze the mechanism of action of gemcitabine. Viral RNA from E30 was detected using RT-PCR at various times points (4, 6, 8, 10, and 12 h post-infection) and after gemcitabine (10 M) and rupintrivir (2 M) treatment of E30-infected cells. We could find E30 viral RNA as early as 8 h post-infection. Interestingly, gemcitabine was seen to block the proliferation of E30 in resemblance to rupintrivir (inhibitor of picornavirus 3C protease, Fig. 2). Based on the results of the time course experiments, we hypothesized that the antiviral effect of gemcitabine occurs relatively early in the infection process. To observe which step is influenced by gemcitabine, we performed a time-of-addition experiment. Gemcitabine (10 M) and rupintrivir (2 M) were added to the culture medium at -1, 0, 1, 2, 4, 6, 8, 10 and 12 h after virus infection. E30 RNA replication was analyzed infection. Therefore, we concluded that the antiviral effect of gemcitabine occurs relatively early during viral infection. To realize the potential of gemcitabine as an antiviral candidate, its mechanism of activity must be understood. It is important to differentiate between viral inactivation (virucidal activity) from antiviral activity. Direct viral inactivation is an early event where the virus is inactivated before it infects the cells while antiviral activity involves killing the virus or the suppression of viral replication. It would be ideal for viral infection treatments to possess both virucidal and antiviral activities. In our study, gemcitabine did not directly interact with E30 particles as pre-exposure of the virus to gemcitabine did not alter the infectivity of E30 particles. Furthermore, addition of UTP and CTP significantly reduced the antiviral activity of gemcitabine by increasing the levels of pyrimidine ","PeriodicalId":39739,"journal":{"name":"Journal of Bacteriology and Virology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4167/jbv.2019.49.4.203","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44536608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-01DOI: 10.4167/jbv.2019.49.4.153
D. Seo, Yong-il Cho, Y. Yi, Sang-Myeong Lee
{"title":"Aralia cordataExtract Activates NF-κB and MAPK Signaling Pathways and Induces Pro-inflammatory Changes in RAW264.7 Macrophages","authors":"D. Seo, Yong-il Cho, Y. Yi, Sang-Myeong Lee","doi":"10.4167/jbv.2019.49.4.153","DOIUrl":"https://doi.org/10.4167/jbv.2019.49.4.153","url":null,"abstract":"","PeriodicalId":39739,"journal":{"name":"Journal of Bacteriology and Virology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4167/jbv.2019.49.4.153","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48172485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-01DOI: 10.4167/jbv.2019.49.3.133
Sun Young Kim, Bo-Kyoung Jung, G. Park, Hye-Ran Kim, D. An, Eun-Ju Shon, Kyung-Soo Chang
Sun-Young Kim, Bo-Kyoung Jung, Gyu-Nam Park, Hye-Ran Kim, Dong-Jun An, Eun-Ju Shon and Kyung-Soo Chang 1Department of Pathology, Dongnam Institute of Radiological and Medical Sciences, Busan 46033, Republic of Korea; 2Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan, Busan 46252, Republic of Korea; 3Animal and Plant Quarantine and Inspection Agency (QIA), 177, Hyeoksin 8-ro, Gimcheon-si, Gyengsangbuk-do 39660 Republic of Korea; 4Department of Clinical Laboratory Science, College of Medical Sciences, Daegu Haany University, Gyeongsan 38610, Republic of Korea; 5BioApplications Inc., Pohang Techno Park Complex, 394 Jigok-ro Nam-gu, Pohang 37668, Korea; 6Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology, Pohang 37673, Korea
{"title":"Histopathological Evaluation of the Efficacy for Plant-produced E2 Protein Vaccine against Classical Swine Fever Virus (CSFV) in Piglets","authors":"Sun Young Kim, Bo-Kyoung Jung, G. Park, Hye-Ran Kim, D. An, Eun-Ju Shon, Kyung-Soo Chang","doi":"10.4167/jbv.2019.49.3.133","DOIUrl":"https://doi.org/10.4167/jbv.2019.49.3.133","url":null,"abstract":"Sun-Young Kim, Bo-Kyoung Jung, Gyu-Nam Park, Hye-Ran Kim, Dong-Jun An, Eun-Ju Shon and Kyung-Soo Chang 1Department of Pathology, Dongnam Institute of Radiological and Medical Sciences, Busan 46033, Republic of Korea; 2Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan, Busan 46252, Republic of Korea; 3Animal and Plant Quarantine and Inspection Agency (QIA), 177, Hyeoksin 8-ro, Gimcheon-si, Gyengsangbuk-do 39660 Republic of Korea; 4Department of Clinical Laboratory Science, College of Medical Sciences, Daegu Haany University, Gyeongsan 38610, Republic of Korea; 5BioApplications Inc., Pohang Techno Park Complex, 394 Jigok-ro Nam-gu, Pohang 37668, Korea; 6Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology, Pohang 37673, Korea","PeriodicalId":39739,"journal":{"name":"Journal of Bacteriology and Virology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4167/jbv.2019.49.3.133","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45700381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}